Athira Pharma, Inc.(ATHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATHA Athira Pharma, Inc.

Closed 12-26 16:00:00 EST

0.5385

-0.0035

-0.65%

盘后0.5281

-0.0104-1.93%

19:58 EST

High0.5427	Low0.5060	Vol587.40K
Open0.5427	D1 Closing0.5420	Amplitude6.77%
Mkt Cap20.82M	Tradable Cap15.04M	Total Shares38.67M
T/O309.40K	T/O Rate2.10%	Tradable Shares27.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ATHA","market":"US","secType":"STK","nameCN":"Athira Pharma, Inc.","latestPrice":0.5385,"timestamp":1735246800000,"preClose":0.542,"halted":0,"volume":587401,"hourTrading":{"tag":"盘后","latestPrice":0.5281,"preClose":0.5385,"latestTime":"19:58 EST","volume":288,"amount":152.9468,"timestamp":1735261103794},"delay":0,"floatShares":27931669,"shares":38669073,"eps":-2.849483,"marketStatus":"Closed","change":-0.0035,"latestTime":"12-26 16:00:00 EST","open":0.5427,"high":0.5427,"low":0.506,"amount":309397.17637224996,"amplitude":0.067712,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.849483,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1735290000000},"marketStatusCode":5,"adr":0,"listingDate":1600401600000,"exchange":"NASDAQ","adjPreClose":0.542,"preHourTrading":{"tag":"盘前","latestPrice":0.542,"preClose":0.542,"latestTime":"09:24 EST","volume":1448,"amount":794.1681976,"timestamp":1735223080249},"postHourTrading":{"tag":"盘后","latestPrice":0.5281,"preClose":0.5385,"latestTime":"19:58 EST","volume":288,"amount":152.9468,"timestamp":1735261103794},"volumeRatio":2.09613,"impliedVol":3.2423,"impliedVolPercentile":0.9048},"requestUrl":"/m/hq/s/ATHA/wiki","defaultTab":"wiki","newsList":[{"id":"2492900257","title":"Athira Pharma Insider Ups Holding By 111% During Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2492900257","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492900257?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:19","pubTimestamp":1734524391,"startTime":"0","endTime":"0","summary":"From what we can see, insiders were net buyers in Athira Pharma, Inc.'s  during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.The Last 12 Months Of Insider Transactions At Athira Pharma. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private d","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/athira-pharma-insider-ups-holding-121951236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATHA","BK4007"],"gpt_icon":0},{"id":"2489145267","title":"Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND","url":"https://stock-news.laohu8.com/highlight/detail?id=2489145267","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489145267?lang=en_us&edition=fundamental","pubTime":"2024-12-07 06:30","pubTimestamp":1733524200,"startTime":"0","endTime":"0","summary":"BOTHELL, Wash., Dec.  06, 2024  (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/06/2993295/0/en/Athira-Pharma-Presents-Preclinical-Data-Highlighting-Neuroprotective-Effects-of-ATH-1105-in-Models-of-ALS-at-Motor-Neurone-Disease-Association-s-35th-International-Symposium-on-ALS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATH","WRD","BK4162","BK4007","PHH","ATHA"],"gpt_icon":0},{"id":"2482139344","title":"Athira Pharma’s Regulatory Compliance Challenges Threaten Drug Development Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2482139344","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482139344?lang=en_us&edition=fundamental","pubTime":"2024-11-09 14:01","pubTimestamp":1731132108,"startTime":"0","endTime":"0","summary":"Athira Pharma, Inc. (ATHA) has disclosed a new risk, in the Regulation category. Athira Pharma, Inc. faces significant business risk due to its dep...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/athira-pharmas-regulatory-compliance-challenges-threaten-drug-development-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/athira-pharmas-regulatory-compliance-challenges-threaten-drug-development-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ATHA"],"gpt_icon":0},{"id":"2482455119","title":"Athira Pharma Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482455119","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482455119?lang=en_us&edition=fundamental","pubTime":"2024-11-09 05:08","pubTimestamp":1731100103,"startTime":"0","endTime":"0","summary":"* Athira Pharma Inc    reported a quarterly adjusted loss of 75 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -87 cents. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Athira Pharma Inc reports results for the quarter ended September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATHA"],"gpt_icon":0},{"id":"2481159821","title":"JMP Securities Keeps Their Hold Rating on Athira Pharma (ATHA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481159821","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481159821?lang=en_us&edition=fundamental","pubTime":"2024-11-08 13:36","pubTimestamp":1731044166,"startTime":"0","endTime":"0","summary":"JMP Securities analyst Jason Butler reiterated a Hold rating on Athira Pharma (ATHA – Research Report) today. The company’s shares closed yesterday...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jmp-securities-keeps-their-hold-rating-on-athira-pharma-atha-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jmp-securities-keeps-their-hold-rating-on-athira-pharma-atha-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHA","JMP"],"gpt_icon":0},{"id":"2481716875","title":"Athira Pharma Q3 EPS $(0.75) Misses $(0.69) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481716875","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481716875?lang=en_us&edition=fundamental","pubTime":"2024-11-08 06:18","pubTimestamp":1731017913,"startTime":"0","endTime":"0","summary":"Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.69) by 8.7 percent. This is a 13.79 percent increase over losses of $(0.87) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41828098/athira-pharma-q3-eps-0-75-misses-0-69-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Athira Pharma Q3 EPS $(0.75) Misses $(0.69) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATHA"],"gpt_icon":0},{"id":"2481150307","title":"Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481150307","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481150307?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:05","pubTimestamp":1731013500,"startTime":"0","endTime":"0","summary":"Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025BOTHELL, Wash., Nov.  07, 2024  (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/07/2977129/0/en/Athira-Pharma-Reports-Third-Quarter-2024-Financial-Results-and-Pipeline-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4178","BK4110","WRD","AAN","ATHA","AAIC","BK4007"],"gpt_icon":0},{"id":"2481360471","title":"Athira Pharma Inc  expected to post a loss of 71 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2481360471","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481360471?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:54","pubTimestamp":1730901293,"startTime":"0","endTime":"0","summary":"Athira Pharma Inc  expected to post a loss of71cents a share - Earnings Preview Athira Pharma Inc ATHA.OQ ATHA.O is expected to show no change in quarterly revenue when it reports  results on November","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nL8N3MD2N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATHA"],"gpt_icon":0},{"id":"2481529258","title":"3 Penny Stocks to Watch Now, 11/5/24","url":"https://stock-news.laohu8.com/highlight/detail?id=2481529258","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481529258?lang=en_us&edition=fundamental","pubTime":"2024-11-05 16:38","pubTimestamp":1730795899,"startTime":"0","endTime":"0","summary":"Vast Renewables, Theriva Biologics, and Athira Pharma are the 3 Penny Stocks to watch on November 5, 2024, based on TipRanks’ Penny Stock Scre...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/3-penny-stocks-to-watch-now-11-5-24?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/3-penny-stocks-to-watch-now-11-5-24?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ATHA"],"gpt_icon":0},{"id":"2481341085","title":"US Penny Stocks: November 2024's Top Picks To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2481341085","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481341085?lang=en_us&edition=fundamental","pubTime":"2024-11-05 01:05","pubTimestamp":1730739902,"startTime":"0","endTime":"0","summary":"As the U.S. stock market navigates a period of uncertainty with investors closely watching the presidential election and upcoming Federal Reserve interest rate decisions, opportunities continue to emerge across various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing investment option due to their affordability and potential for growth. This article explores three penny stocks that stand out for their financial strength and resilience in today's market landscape.Let's dive into some prime choices out of the screener.Overview: Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company dedicated to developing small molecules aimed at restoring neuronal health and slowing neurodegeneration, with a market cap of $23.29 million.Operations: The company generates CA$17.13 million from its energy compliance and consulting services segment.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-penny-stocks-november-2024s-170502022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHX","RLX","BK4526","BK4075","BK4209","BK4007","BK4563","BABB","BK4213","ARC","BK4551","BK4143","ATHA"],"gpt_icon":0},{"id":"2480155433","title":"Terra Uranium targets high-grade deposits at Spire and Horizon projects in Canada’s Athabasca Basin","url":"https://stock-news.laohu8.com/highlight/detail?id=2480155433","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480155433?lang=en_us&edition=fundamental","pubTime":"2024-11-04 06:51","pubTimestamp":1730674291,"startTime":"0","endTime":"0","summary":"Terra Uranium  has commenced exploration at the historic Spire and Horizon projects on the eastern rim of Canada’s Athabasca Basin, under an option agreement with ATHA Energy.The company has mobilised to the site for an initial work program comprising airborne geophysics – including gravity, magnetics and radiometrics surveys – and ground reconnaissance work to follow up on historic mineralised boulder samples.Exploration will target basement-hosted, near-surface uranium deposits along prominent structural corridors and is expected to be completed within the week.Terra’s exploration is being conducted in accordance with the terms of an option agreement signed in October with ATHA Energy, which requires Terra to spend $820,000 on Spire and Horizon before the end of December.Terra and ATHA will form a joint venture over Spire and Horizon projects after the third expenditure, whereby Terra will hold a 50% participating interest and ATHA will retain a 50% free-carried interest.Once Terra h","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Terra-Uranium-ASX-T92-ATHA-Spire-Horizon-commencement.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Terra-Uranium-ASX-T92-ATHA-Spire-Horizon-commencement.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://smallcaps.com.au/terra-uranium-high-grade-deposits-spire-horizon-athabasca-basin/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK4197","T92.AU","BK4007","BK4156","SR","UEC","ATHA","BK7083"],"gpt_icon":0},{"id":"2480888717","title":"BUZZ-U.S. STOCKS ON THE MOVE-Intel, Abbott, Boeing","url":"https://stock-news.laohu8.com/highlight/detail?id=2480888717","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480888717?lang=en_us&edition=fundamental","pubTime":"2024-11-01 20:40","pubTimestamp":1730464809,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Intel, Abbott, BoeingEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241101:nL4N3M81A3:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0612318971.USD","BK4077","BK4551","WMPN","LU0068578508.USD","DBRG","CVX","W","BK4561","IE00B2B36J28.USD","HALO","LU1162221912.USD","LU0234572021.USD","LU1489326972.SGD","ATHA","LU1929549753.HKD","MPB","BK4161","CPS","FWONA","LU2326559502.SGD","LU0149725797.USD","LU2237438978.USD","NRGV","SIRI","LU1066053197.SGD","LU1496350502.SGD","LU0942090050.USD","PDEX","XOM","BK4554","BK4122","PRLB","LU0320765489.SGD","BK4139","LU1435385759.SGD","LXRX","BK4524","BA","LU0787776722.HKD","LU1150488218.USD","VSME","INTC","BK4187","LU0985489474.SGD","ELAB","BK4592","ABT","LU0203345920.USD","LU0256863811.USD"],"gpt_icon":1},{"id":"2480040183","title":"Terra Uranium Kicks Off Exploration Projects with ATHA","url":"https://stock-news.laohu8.com/highlight/detail?id=2480040183","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480040183?lang=en_us&edition=fundamental","pubTime":"2024-11-01 13:12","pubTimestamp":1730437934,"startTime":"0","endTime":"0","summary":"Terra Uranium Limited (AU:T92) has released an update. Terra Uranium Limited has begun field operations on its Spire & Horizon Projects in partners...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/terra-uranium-kicks-off-exploration-projects-with-atha?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/terra-uranium-kicks-off-exploration-projects-with-atha?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHA","UEC","BK4007","BK4156"],"gpt_icon":0},{"id":"2479700804","title":"BRIEF-Atha Energy Announces Appointment Of New Board Member And Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2479700804","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479700804?lang=en_us&edition=fundamental","pubTime":"2024-10-29 19:15","pubTimestamp":1730200553,"startTime":"0","endTime":"0","summary":"Oct 29  - ATHA Energy Corp   :   * ATHA ENERGY ANNOUNCES APPOINTMENT OF NEW BOARD MEMBER AND CHIEF FINANCIAL OFFICER   * ATHA ENERGY CORP - APPOINTS RHAL ASSI AS CFO EFFECTIVE NOVEMBER 6, 2024   * ATHA ENERGY CORP - JEFFREY BARBER RESIGNS FROM BOARD, AKASH PATEL RESIGNS AS CFOSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ATHA"],"gpt_icon":0},{"id":"2477342432","title":"Terra Uranium ready to step up work on Canadian uranium portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2477342432","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477342432?lang=en_us&edition=fundamental","pubTime":"2024-10-23 11:38","pubTimestamp":1729654711,"startTime":"0","endTime":"0","summary":"Australia’s Terra Uranium  is set to accelerate its two-pronged Canadian exploration and development strategy, with the signing of new definitive option agreements earlier this month.The company’s executive chair Andrew Vigar told the Global Uranium Conference in Adelaide that Terra has a unique position in some of the world’s most prospective uranium areas.The company holds a 100% interest in the Engler Lake, HawkRock, Parker Lake, Rapid River and Yurkowski Lake projects, located in the Cable Bay Shear Zone on the eastern side of the prolific Athabasca Basin in Saskatchewan.Earlier this month, Terra and TSXV-listed ATHA Energy confirmed their previously announced plans to work together to progress three Canadian uranium projects.Under the agreements, ATHA has an option to acquire up to 60% of Terra’s Pasfield Lake project, with Terra having an option to acquire up to 70% of ATHA’s Spire and Horizon projects.Amer Lake is covered by eight claims totalling approximately 27 square kilomet","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/10/Terra-Uranium-ASX-T92-global-conference-presentation.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/10/Terra-Uranium-ASX-T92-global-conference-presentation.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://smallcaps.com.au/terra-uranium-ready-step-up-work-canadian-uranium-portfolio/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK4007","BK4156","ATHA","T92.AU","BK7083","UEC"],"gpt_icon":0},{"id":"2477387482","title":"Athira Pharma to present results from Phase 2/3 LIFT-AD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2477387482","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477387482?lang=en_us&edition=fundamental","pubTime":"2024-10-22 19:21","pubTimestamp":1729596069,"startTime":"0","endTime":"0","summary":"Athira Pharma (ATHA) announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease will be presente...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/athira-pharma-to-present-results-from-phase-2-3-lift-ad-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/athira-pharma-to-present-results-from-phase-2-3-lift-ad-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHA","BK4007"],"gpt_icon":0},{"id":"2477382641","title":"Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2477382641","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477382641?lang=en_us&edition=fundamental","pubTime":"2024-10-22 19:00","pubTimestamp":1729594800,"startTime":"0","endTime":"0","summary":"BOTHELL, Wash., Oct. 22, 2024  -- Athira Pharma, Inc. , a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease  will be presented at the 17th Annual Clinical Trials on Alzheimer’s Disease  taking place October 29 - November 1, 2024, in Madrid, Spain.Title: Fosgonimeton for the Treatment of Alzheimer’s Disease; Efficacy and Safety Results from the LIFT-AD TrialSession: Oral Communications: OC2 Date/Time: Tuesday, October 29 at 5:10 p.m., CETPresenter: Anton P. Porsteinsson, M.D., Director of the University of Rochester Alzheimer’s Disease Care, Research, and Education Program  and a LIFT-AD investigator. About Athira Pharma, Inc.Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neur","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fsHQWdqYpDOIPIK4nkaHxA--~B/aD0xODIwO3c9MzY0NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/3e339943e10430294dca439e62ca4396","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fsHQWdqYpDOIPIK4nkaHxA--~B/aD0xODIwO3c9MzY0NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/3e339943e10430294dca439e62ca4396"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/athira-pharma-present-results-phase-110000917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATHA","GST","BK4007","WRD"],"gpt_icon":0},{"id":"2477483011","title":"Athira Pharma files $300M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2477483011","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477483011?lang=en_us&edition=fundamental","pubTime":"2024-10-21 18:31","pubTimestamp":1729506701,"startTime":"0","endTime":"0","summary":"06:26 EDT Athira Pharma (ATHA) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/athira-pharma-files-300m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/athira-pharma-files-300m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHA","BK4007"],"gpt_icon":0},{"id":"2477837020","title":"Athira Pharma Inc - Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2477837020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477837020?lang=en_us&edition=fundamental","pubTime":"2024-10-21 18:25","pubTimestamp":1729506358,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nFWN3LX0MD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ATHA"],"gpt_icon":0},{"id":"2476216755","title":"BRIEF-Athira Pharma Receives Nasdaq Non-Compliance Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2476216755","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476216755?lang=en_us&edition=fundamental","pubTime":"2024-10-19 04:07","pubTimestamp":1729282029,"startTime":"0","endTime":"0","summary":"Oct 18 (Reuters) - Athira Pharma Inc   :   * ATHIRA PHARMA: RECEIVES NASDAQ NON-COMPLIANCE NOTICE   * ATHIRA PHARMA: CO HAS UNTIL APRIL 14, 2025, TO REGAIN COMPLIANCESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","QID","QLD",".IXIC","SQQQ","IE00BKPKM429.USD","BK4588","TQQQ","NDAQ","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","PSQ","LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4585","MNQmain","ATHA","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.athira.com","stockEarnings":[{"period":"1week","weight":-0.0767},{"period":"1month","weight":-0.1558},{"period":"3month","weight":0.2406},{"period":"6month","weight":-0.7947},{"period":"1year","weight":-0.7491},{"period":"ytd","weight":-0.777}],"compareEarnings":[{"period":"1week","weight":-0.0049},{"period":"1month","weight":0.0097},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.1005},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.2651}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.002015},{"month":2,"riseRate":0.5,"avgChangeRate":-0.024771},{"month":3,"riseRate":0.25,"avgChangeRate":-0.042184},{"month":4,"riseRate":0.5,"avgChangeRate":-0.083309},{"month":5,"riseRate":0.5,"avgChangeRate":0.0546},{"month":6,"riseRate":0.5,"avgChangeRate":-0.268531},{"month":7,"riseRate":0.5,"avgChangeRate":0.068267},{"month":8,"riseRate":0.25,"avgChangeRate":-0.048602},{"month":9,"riseRate":0,"avgChangeRate":-0.296349},{"month":10,"riseRate":0.4,"avgChangeRate":0.043668},{"month":11,"riseRate":0.6,"avgChangeRate":0.160649},{"month":12,"riseRate":0.6,"avgChangeRate":0.175228}],"exchange":"NASDAQ","name":"Athira Pharma, Inc.","nameEN":"Athira Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Athira Pharma, Inc.(ATHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Athira Pharma, Inc.(ATHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Athira Pharma, Inc.,ATHA,Athira Pharma, Inc.股票,Athira Pharma, Inc.股票老虎,Athira Pharma, Inc.股票老虎国际,Athira Pharma, Inc.行情,Athira Pharma, Inc.股票行情,Athira Pharma, Inc.股价,Athira Pharma, Inc.股市,Athira Pharma, Inc.股票价格,Athira Pharma, Inc.股票交易,Athira Pharma, Inc.股票购买,Athira Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Athira Pharma, Inc.(ATHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Athira Pharma, Inc.(ATHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction